POINT Biopharma Global Inc. (NASDAQ:PNT) Given Consensus Recommendation of “Hold” by Brokerages
POINT Biopharma Global Inc. (NASDAQ:PNT – Get Free Report) has earned an average rating of “Hold” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a hold recommendation. The average twelve-month target price among brokerages that have covered the stock in the […]
More Stories
West Oak Capital LLC Acquires 3,109 Shares of iShares Core S&P 500 ETF (NYSEARCA:IVV)
West Oak Capital LLC raised its holdings in iShares Core S&P 500 ETF (NYSEARCA:IVV – Free Report) by 287.6% in...
Progyny (NASDAQ:PGNY) Shares Up 3.1% – Should You Buy?
Progyny, Inc. (NASDAQ:PGNY – Get Free Report)’s stock price shot up 3.1% on Wednesday . The stock traded as high...
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 6.7% – Here’s What Happened
Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Get Free Report) traded down 6.7% on Wednesday . The company traded...
PayPal (NASDAQ:PYPL) Shares Down 0.3% – Here’s Why
PayPal Holdings, Inc. (NASDAQ:PYPL – Get Free Report)’s stock price traded down 0.3% during mid-day trading on Wednesday . The...
Invesco QQQ (NASDAQ:QQQ) Stock Price Up 0% – Here’s Why
Invesco QQQ (NASDAQ:QQQ – Get Free Report)’s share price shot up 0% during mid-day trading on Wednesday . The stock...
Ecor1 Capital, Llc Purchases 21,021 Shares of Zymeworks Inc. (NYSE:ZYME) Stock
Zymeworks Inc. (NYSE:ZYME – Get Free Report) Director Ecor1 Capital, Llc purchased 21,021 shares of Zymeworks stock in a transaction...